Cell No. : Cell Name RCB3567 : ATL-26C(+)  update : 2024/10/02
Comment			BSL2. Currently not ready. We don't know whether virus particles are produced or not. Therefore, the cells must be handled under BSL2.
Comment from the depositor			Non-leukemic cell line (IL-2 dependent).
Terms and conditions
Remarks
Order Form
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Expected time	Upon a request we will start preparation. Contact us: cellkitaku.brc@riken.jp
		BSL	BSL2
		Cellosaurus(Expasy)	CVCL_A6SU
Reference information		Reference	2
		User's Publication	0

Top

Reference

3175  Michiyuki Maeda, Junko Tanabe-Shibuya, Paola Miyazato, Hiroshi Masutani, Jun-Ichirou Yasunaga, Kazumasa Usami, Akira Shimizu, Masao Matsuoka  IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia  Front Microbiol  2020  11:356  PubMed ID: 32210945   DOI: 10.3389/fmicb.2020.00356

2508  Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H, Maeda M, Yagita H, Komatsu N, Hino O.  Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation  PLoS One  2016  11(3):e0150496.  PubMed ID: 27028595   DOI: 10.1371/journal.pone.0150496

Top

User's Publication